Penn Global Medicine (PGM)

Clinical Programs

Penn Transplant Institute

The expertise and experience of Penn's transplant teams distinguishes the Penn Transplant Institute from other transplant programs. Their outcomes are consistently outstanding for all organ transplants including multiple organ combinations such as liver-lung and heart-liver.

About Transplantation at Penn

More than 400 solid organ transplants are performed at Penn annually. Survival outcomes consistently exceed the national average.

Penn has been a pioneer in organ transplantation for more than 40 years, performing its first successful kidney transplant in 1966. Penn Transplant Institute leads the region in total number of the transplants performed.

For specific information, click on a program below:

Living Donor Transplantation at Penn

Living donation occurs when a living person donates an organ or piece of an organ to someone in need of a transplant. Penn Medicine kidney and liver living donor programs are among the oldest and most experienced in the United States. Both programs have national and international reputations for excellence.

Penn is one of only nine programs in the United States participating in adult-to-adult living donor research conducted by the prestigious National Institutes of Health.

A joint program with The Children's Hospital of Philadelphia allows healthy adult relatives to donate organ tissue to children with end-stage kidney and liver disease.

The Penn Difference

Penn is at the forefront of transplant research with innovative trials to investigate:

  • Mechanical circulatory support devices as destination therapy for heart failure.
  • Innovative trials in desensitization.
  • Improved protection from infectious disease in transplant patients.
  • Robust research in islet cell transplantation.
  • Immuno-suppression minimization and complete withdrawal.
  • Non-invasive biomarkers of graft rejection.
  • Genetic predictors for the treatment of hepatitis C after transplantation.
  • Cutting-edge and novel therapies for viral hepatitis.
  • Novel biomarkers for liver cancer screening.